[{"address1": "12770 High Bluff Drive", "address2": "Suite 150", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "619-949-3681", "website": "https://www.gyretx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis. In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.", "fullTimeEmployees": 593, "companyOfficers": [{"maxAge": 1, "name": "Dr. Han  Ying Ph.D.", "age": 57, "title": "CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 10500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Songjiang  Ma", "age": 67, "title": "President & Director", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Ruoyu  Chen", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 121352, "exercisedValue": 0, "unexercisedValue": 15073756}, {"maxAge": 1, "name": "Mr. Weiguo  Ye", "age": 45, "title": "Chief Operating Officer", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 274617, "exercisedValue": 0, "unexercisedValue": 41527968}, {"maxAge": 1, "name": "Ms. Seline E. Miller CPA", "age": 53, "title": "Senior Vice President of Finance", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 9, "governanceEpochDate": 1730419200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.97, "open": 15.52, "dayLow": 14.728, "dayHigh": 15.71, "regularMarketPreviousClose": 14.97, "regularMarketOpen": 15.52, "regularMarketDayLow": 14.728, "regularMarketDayHigh": 15.71, "forwardPE": 34.021736, "volume": 61860, "regularMarketVolume": 61860, "averageVolume": 47206, "averageVolume10days": 30860, "averageDailyVolume10Day": 30860, "bid": 11.28, "ask": 19.13, "bidSize": 200, "askSize": 200, "marketCap": 1462088704, "fiftyTwoWeekLow": 8.26, "fiftyTwoWeekHigh": 30.4, "priceToSalesTrailing12Months": 13.102679, "fiftyDayAverage": 13.46, "twoHundredDayAverage": 14.1252, "currency": "USD", "enterpriseValue": 1349628544, "profitMargins": -0.77042997, "floatShares": 15817936, "sharesOutstanding": 93424200, "sharesShort": 448696, "sharesShortPriorMonth": 308405, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0047999998, "heldPercentInsiders": 0.74704003, "heldPercentInstitutions": 0.01381, "shortRatio": 7.6, "shortPercentOfFloat": 0.0313, "bookValue": 0.706, "priceToBook": 22.16714, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.904, "netIncomeToCommon": -85970000, "trailingEps": -1.05, "forwardEps": 0.46, "enterpriseToRevenue": 12.095, "enterpriseToEbitda": 67.209, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GYRE", "underlyingSymbol": "GYRE", "shortName": "Gyre Therapeutics, Inc.", "longName": "Gyre Therapeutics, Inc.", "firstTradeDateEpochUtc": 1144848600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "fcf12068-c88b-34d0-8632-7e45e01ea8d2", "gmtOffSetMilliseconds": -18000000, "currentPrice": 15.65, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 25100000, "totalCashPerShare": 0.293, "ebitda": 20081000, "totalDebt": 1956000, "quickRatio": 2.871, "currentRatio": 3.436, "totalRevenue": 111587000, "debtToEquity": 2.095, "revenuePerShare": 1.464, "returnOnAssets": 0.10181, "returnOnEquity": -0.82741, "freeCashflow": 8442836, "operatingCashflow": 8333000, "earningsGrowth": -0.705, "revenueGrowth": -0.14, "grossMargins": 0.96251, "ebitdaMargins": 0.17996, "operatingMargins": 0.12932, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-07"}]